NVO

Viking Therapeutics’ inventory greater than doubles as traders cheer low cost entry to weight-loss-drug craze

This grouping of shares has truly stored up with the Magnificent Seven, and with lots much less danger

What to consider ‘Peak 65’

Novo Nordisk’s controlling shareholder to purchase Catalent for $16.5 billion

It’s shaping as much as be an awesome quarter for Europe’s largest firms — no because of Europe.

Ozempic maker Novo Nordisk reviews 62% surge in revenue

Omega Therapeutics inventory greater than doubles on Novo Nordisk weight problems drug analysis pact

Five obesity-drug tendencies to observe in 2024: Who can compete with Eli Lilly and Novo Nordisk? 

Novo Nordisk, FDA warn of faux Ozempic

Nvidia, Disney and Tesla are amongst 2023’s buzziest shares. Can they proceed to sizzle in 2024?